Journal: Human Vaccines & Immunotherapeutics
Article Title: NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants
doi: 10.1080/21645515.2026.2638022
Figure Lengend Snippet: Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; BNT162b2), first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.
Article Snippet: In Singapore, the bivalent mRNA-1273 (ancestral/BA.1, Moderna) and bivalent BNT162b2 (ancestral/BA.4/5, Pfizer) vaccines were added to the National Vaccination Programme from October 2022 and were recommended in place of the original monovalent vaccines.
Techniques: Comparison, Infection